Diabetes treatment in 2025: Can scientific advances keep pace with prevalence?

Therapeutic Advances in Endocrinology and Metabolism

Volumn 3, Issue 5, 2012, Pages 163-173

  Shomali, Mansur ^a  

^a UNION MEMORIAL HOSPITAL   (United States)

Author keywords

hypoglycemic agents; obesity; prevalence; translational medical research; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; BROMOCRIPTINE; BUFORMIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ETANERCEPT; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERLEUKIN 6; METFORMIN; PHENFORMIN; PRAMLINTIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RESVERATROL; RIMONABANT; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACROMEGALY; ARTICLE; ARTIFICIAL PANCREAS; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; BRAIN ISCHEMIA; BRAIN REGION; CALORIC RESTRICTION; CELL PROTECTION; CELL TYPE; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; ENERGY BALANCE; ENERGY EXPENDITURE; ENZYME ACTIVATION; GLYCEMIC CONTROL; GRAFT REJECTION; GRAFT SURVIVAL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPOGLYCEMIA; LACTIC ACIDOSIS; MEDICAL RESEARCH; METABOLIC REGULATION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORGAN DONOR; OVERNUTRITION; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PREVALENCE; PRIORITY JOURNAL; SATIETY; SEDENTARY LIFESTYLE; SIGNAL TRANSDUCTION; SLEEVE GASTRECTOMY; STOMACH BYPASS; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 84868285277     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018812465639     Document Type: Article

References (72)

1. Alejandro R. Barton F. Hering B. Wease S. (2008) 2008 update from the Collaborative Islet Transplant Registry. Transplantation 86: 1783–1788.
2. American Diabetes Association (2012) Standards of medical care in diabetes–2012. Diabetes Care 35(Suppl. 1): S11–S63.
3. Baiu D. Merriam F. Odorico J. (2011) Potential pathways to restore beta-cell mass: pluripotent stem cells, reprogramming, and endogenous regeneration. Curr Diab Rep 11: 392–401.
4. Barone P. Strano M. (2009) Single walled carbon nanotubes as reporters for the optical detection of glucose. J Diabetes Sci Technol 3: 242–252.
5. Bergenstal R. Tamborlane W. Ahmann A. Buse J. Dailey G. Davis S. et al. (2010) Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 363: 311–320.
6. Bernstein L. Berry J. Kim S. Canavan B. Grinspoon S. (2006) Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166: 902–908.
7. Ceriello A. Motz E. (2004) Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 24: 816–823.
8. Cincotta A. Meier A. Cincotta M. Jr. (1999) Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 8: 1683–1707.
9. Claiborn K. Stoffers D. (2008) Toward a cell-based cure for diabetes: advances in production and transplant of beta cells. Mt Sinai J Med 75: 362–371.
10. de Silva A. Salem V. Long C. Makwana A. Newbould R. Rabiner E. et al. (2011) The gut hormones PYY3-36 and GLP-17-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 14: 700–706.
11. Dhahbi J. Mote P. Fahy G. Spindler S. (2005) Identification of potential caloric restriction mimetics by microarray profiling. Physiol Genomics 23: 343–350.
12. Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986.
13. Eckel R. Kahn S. Ferrannini E. Goldfine A. Nathan D. Schwartz M. et al. (2011) Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care 34: 1424–1430.
14. El-Khatib F. Russell S. Nathan D. Sutherlin R. Damiano E. (2010) A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2 (27): 27ra27.
15. Elbel B. Cantor J. Mijanovich T. (2012) Potential effect of the New York City policy regarding sugared beverages. N Engl J Med 367: 680–681.
16. Esparza-Romero J. Valencia M. Martinez M. Ravussin E. Schulz L. Bennett P. (2010) Differences in insulin resistance in Mexican and US Pima Indians with normal glucose tolerance. J Clin Endocrinol Metab 95: E358–E362.
17. Fakhrudin N. Ladurner A. Atanasov A. Heiss E. Baumgartner L. Markt P. et al. (2010) Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma. Mol Pharmacol 77: 559–566.
18. Foretz M. Hebrard S. Leclerc J. Zarrinpashneh E. Soty M. Mithieux G. et al. (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120: 2355–2369.
19. Fryer L. Parbu-Patel A. Carling D. (2002) The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277: 25226–25232.
20. Gardner D. Tai E. (2012) Clinical features and treatment of maturity onset diabetes of the young (MODY). Diabetes Metab Syndr Obes 5: 101–108.
21. Gaziano J. Cincotta A. O'Connor C. Ezrokhi M. Rutty D. Ma Z. et al. (2010) Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 33: 1503–1508.
22. Gruessner A. (2011) 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud 8: 6–16.
23. Gruzman A. Babai G. Sasson S. (2009) Adenosine monophosphate-activated protein kinase (AMPK) as a new target for antidiabetic drugs: a review on metabolic, pharmacological and chemical considerations. Rev Diabet Stud 6: 13–36.
24. Hermanides J. Norgaard K. Bruttomesso D. Mathieu C. Frid A. Dayan C. et al. (2011) Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet Med 28: 1158–1167.
25. Hochberg L. Serruya M. Friehs G. Mukand J. Saleh M. Caplan A. et al. (2006) Neuronal ensemble control of prosthetic devices by a human with tetraplegia. Nature 442: 164–171.
26. Kelly C. Flatt C. McClenaghan N. (2011) Stem cell-based approaches for the treatment of diabetes. Stem Cells Int 2011: 424986.
27. Knauf C. Cani P. Kim D. Iglesias M. Chabo C. Waget A. et al. (2008) Role of central nervous system glucagon-like peptide-1 receptors in enteric glucose sensing. Diabetes 57: 2603–2612.
28. Kojima H. Fujimiya M. Matsumura K. Younan P. Imaeda H. Maeda M. et al. (2003) NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat Med 9: 596–603.
29. Lagouge M. Argmann C. Gerhart-Hines Z. Meziane H. Lerin C. Daussin F. et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT 1 and PGC-1alpha. Cell 127: 1109–1122.
30. Larsen C. Faulenbach M. Vaag A. Ehses J. Donath M. Mandrup-Poulsen T. (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32: 1663–1668.
31. Larsen C. Faulenbach M. Vaag A. Volund A. Ehses J. Seifert B. et al. (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356: 1517–1526.
32. Lee N. Norris S. Thakurta S. (2012) Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus. Ann Fam Med 8: 542–549.
33. Lim E. Hollingsworth K. Aribisala B. Chen M. Mathers J. Taylor R. (2011) Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54: 2506–2514.
34. Lindstrom J. Neumann A. Sheppard K. Gilis-Januszewska A. Greaves C. Handke U. et al. (2010) Take action to prevent diabetes - the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res 42(Suppl. 1): S37–S55.
35. Lorenzi M. (2007) The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res 2007: 61038.
36. Martin S. (2008) Mammalian hibernation: a naturally reversible model for insulin resistance in man? Diab Vasc Dis Res 5: 76–81.
37. Mattison J. Roth G. Beasley T. Tilmont E. Handy A.M. Herbert R.L. et al. (2012) Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 489: 318–321.
38. Mingrone G. Panunzi S. de Gaetano A. Guidone C. Iaconelli A. Leccesi L. et al. (2012) Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366: 1577–1585.
39. Narkar V. Downes M. Yu R. Embler E. Wang Y. Banayo E. et al. (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell 134: 405–415.
40. Noto H. Goto A. Tsujimoto T. Noda M. (2012) Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PloS ONE 7: e33411.
41. Olefsky J. Glass C. (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72: 219–246.
42. Olshansky S. Passaro D. Hershow R. Layden J. Carnes B. Brody J. et al. (2005) A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 352: 1138–1145.
43. Pagotto U. (2009) Where does insulin resistance start? The brain. Diabetes Care 32(Suppl. 2): S174–S177.
44. Paulweber B. Valensi P. Lindstrom J. Lalic N. Greaves C. McKee M. et al. (2010) A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 42(Suppl. 1): S3–S36.
45. Peterli R. Steinert R. Woelnerhanssen B. Peters T. Christoffel-Courtin C. Gass M. et al. (2012) Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg 22: 740–748.
46. Plesner A. Verchere C. (2011) Advances and challenges in islet transplantation: islet procurement rates and lessons learned from suboptimal islet transplantation. J Transplant 2011: 979527.
47. Powell A. Apovian C. Aronne L. (2011) New drug targets for the treatment of obesity. Clin Pharmacol Ther 90: 40–51.
48. Quinn C. Shardell M. Terrin M. Barr E. Ballew S. Gruber-Baldini A. (2011) Cluster-randomized trial of a mobile phone personalized behavioral intervention for blood glucose control. Diabetes Care 34: 1934–1942.
49. Renard E. (2008) Insulin delivery route for the artificial pancreas: subcutaneous, intraperitoneal, or intravenous? Pros and cons. J Diabetes Sci Technol 2: 735–738.
50. Ross R. (1999) Atherosclerosis – an inflammatory disease. N Engl J Med 340: 115–126.
51. Sachdeva M. Stoffers D. (2009) Minireview: Meeting the demand for insulin: molecular mechanisms of adaptive postnatal beta-cell mass expansion. Mol Endocrinol 23: 747–758.
52. Saltiel A. (2000) Series introduction: the molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases. J Clin Invest 106: 163–164.
53. Schauer P. Kashyap S. Wolski K. Brethauer S. Kirwan J. Pothier C. et al. (2012) Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366: 1567–1576.
54. Schmidt A. Stern D. (2000) RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 11: 368–375.
55. Schwartz J. Riis J. Elbel B. Ariely D. (2012) Inviting consumers to downsize fast-food portions significantly reduces calorie consumption. Health Aff (Millwood) 31: 399–407.
56. Scranton R. Cincotta A. (2010) Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother 11: 269–279.
57. Shapiro A. Lakey J. Ryan E. Korbutt G. Toth E. Warnock G. et al. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343: 230–238.
58. Sovik T. Aasheim E. Taha O. Engstrom M. Fagerland M. Bjorkman S. et al. (2011) Weight loss, cardiovascular risk factors, and quality of life after gastric bypass and duodenal switch: a randomized trial. Ann Intern Med 155: 281–291.
59. Tahrani A. Bailey C. Del Prato S. Barnett A. (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet 378: 182–197.
60. Timmers S. Konings E. Bilet L. Houtkooper R. van de Weijer T. Goossens G. et al. (2011) Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14: 612–622.
61. Truong W. Shapiro A. (2006) Progress in islet transplantation in patients with type 1 diabetes mellitus. Treat Endocrinol 5: 147–158.
62. United Kingdom Prospective Diabetes Study Group (1995) United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310: 83–88.
63. United Kingdom Prospective Diabetes Study Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865.
64. Vaisrub S. (1972) Serendipitous sulphonylureas. JAMA 219: 1335.
65. van Belle T. Coppieters K. von Herrath M. (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91: 79–118.
66. Vero Science (2010) CYCLOSET® (bromocriptine mesylate) Tablets, oral. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020866s002lbl.pdf.
67. Viollet B. Lantier L. Devin-Leclerc J. Hebrard S. Amouyal C. Mounier R. et al. (2009) Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front Biosci 14: 3380–3400.
68. Watson A. Soro-Paavonen A. Sheehy K. Li J. Calkin A. Koitka A. et al. (2011) Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 54: 681–689.
69. Weinzimer S. Tamborlane W. (2008) Sensor-augmented pump therapy in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 15: 118–122.
70. Whiting D. Guariguata L. Weil C. Shaw J. (2011) IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311–321.
71. Witters L. (2001) The blooming of the French lilac. J Clin Invest 108: 1105–1107.
72. Zhou G. Myers R. Li Y. Chen Y. Shen X. Fenyk-Melody J. et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174.